Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07705555 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

A Clinical Trial of MK-8748 Compared to Aflibercept in Participants With Diabetic Macular Edema (MK-8748-004)

StatusRecruiting
PhasePhase 3
Started2026-08-27
View on ClinicalTrials.gov ↗

Amendment history

2026-09-29
Trial sites expanded: 8 → 12 locations
2026-09-11
Study Status, Contacts/Locations v2
Trial sites expanded: 12 → 18 locations
Trial sites expanded: 3 → 6 locations
2026-09-01
Study Status, Contacts/Locations v1
Recruitment opened
Trial sites expanded: 0 → 3 locations
Start dateestimated 2026-08-28→confirmed 2026-08-27
2026-07-10
Original filing
Merck (MSD)
401 trials monitored
See 24 trials at risk
Researchers are looking for new ways to treat diabetic macular edema (DME). In this trial, researchers want to learn if a trial medicine called MK-8748 can treat DME. An available standard (usual) treatment for DME is aflibercept. However, standard treatments such as aflibercept may not work for every person. The main goal of this trial is to learn if MK-8748 works as well as aflibercept to treat DME.
Trial Details
NCT Number NCT07705555
Lead Sponsor Merck Sharp & Dohme LLC
Conditions Diabetic Retinopathy, Macular Edema
Enrollment 960 participants
Start Date 2026-08-27
Primary Completion 2028-10-31 (estimated)
Study Completion 2029-10-31 (estimated)
Updated on ClinicalTrials.gov 2026-10-01